OCUNEXUS THERAPEUTICS
Ocunexus Therapeutics is a biopharmaceutical company that develops therapeutics for unmet clinical needs in ophthalmology. The company specializes in developing highly differentiated drug candidates based upon a novel mechanism of action called “Gap Junction Channel Modulation.” It has developed treatments for multiple front- and back-of-the-eye diseases and disorders that would potentially alter the standard of care. In addition, the company's technologies are expected to be transferable to other acute and chronic disease indications. Ocunexus is formerly known as CoDa Therapeutics, a pharmaceutical company focused on the development and commercialization of wound care therapeutics based on gap junction modulation. The company is based in San Diego, California.
OCUNEXUS THERAPEUTICS
Industry:
Biotechnology Health Care Medical Pharmaceutical Therapeutics
Founded:
2005-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.ocunexus.com
Total Employee:
1+
Status:
Closed
Contact:
(858) 677-0474
Email Addresses:
[email protected]
Total Funding:
78.59 M USD
Similar Organizations
Celator Pharmaceuticals
Celator Pharmaceuticals is a biopharmaceutical company developing therapies to treat cancer, using the drug ratio technology platform.
Current Advisors List
Current Employees Featured
Founder
Investors List
BioPacific Ventures
BioPacific Ventures investment in Series B - Ocunexus Therapeutics
RMI Partners
RMI Partners investment in Series B - Ocunexus Therapeutics
GBS Ventures
GBS Ventures investment in Series B - Ocunexus Therapeutics
Domain Associates
Domain Associates investment in Series B - Ocunexus Therapeutics
Square 1 Bank
Square 1 Bank investment in Debt Financing - Ocunexus Therapeutics
BioPacific Ventures
BioPacific Ventures investment in Series B - Ocunexus Therapeutics
GBS Ventures
GBS Ventures investment in Series B - Ocunexus Therapeutics
Domain Associates
Domain Associates investment in Series B - Ocunexus Therapeutics
Domain Associates
Domain Associates investment in Series A - Ocunexus Therapeutics
GBS Ventures
GBS Ventures investment in Series A - Ocunexus Therapeutics
Official Site Inspections
http://www.ocunexus.com
- Host name: 198.185.159.145
- IP address: 198.185.159.145
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "Ocunexus Therapeutics" on Search Engine
InflammX Therapeutics Company Profile - Craft
InflammX Therapeutics (formerly known as Ocunexus Therapeutics) is a biopharmaceutical company developing therapeutics for ophthalmologic diseases. Its …See details»
Domain Associates-backed OcuNexus Therapeutics …
Aug 8, 2019 Domain Associates-backed OcuNexus Therapeutics Making Significant Progress with Inflammasome Inhibition Program in Ophthalmic Disease with Key …See details»
OcuNexus Therapeutics Making Progress with Inflammasome …
4 days ago OcuNexus Therapeutics is a clinical stage biotechnology company developing a first-in-class orally administered treatment for the dry form of age-related macular …See details»
Epilepsy Pipeline: Insights into Novel and Emerging
Las Vegas, USA, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Epilepsy Pipeline: Insights into Novel and Emerging Pipeline Therapies, Key Pharma Players, Clinical Trials, Growth …See details»
OcuNexus | VentureRadar
Founded in 2005. Private Company. Develops novel therapeutics targeting NLRP3 inflammasome in autoinflammatory diseases, focusing on modulating dysregulated …See details»
Domain Associates-backed OcuNexus Therapeutics Making
Aug 8, 2019 SAN DIEGO - OcuNexus Therapeutics, a clinical stage biotechnology company developing a first-in-class orally administered treatment for the dry form of age …See details»
Brian Levy, OD, MSc | Ophthalmology Innovation Source
Biography. Dr. Levy is currently CEO of Ocunexus Therapeutics a clinical stage company developing ophthalmic products. Ocunexus compounds target Connexin43 Hemichannels inhibiting activation of the …See details»
Therapeutic strategies targeting connexins - Nature
Oct 12, 2018 The successes and failures of first-generation connexin therapeutics designed to treat acute and chronic diseases and injuries, including ischaemia–reperfusion injury (IRI), diabetic ulcers and...See details»
Eyevance Acquires Global Rights to Persistent Corneal
Mar 22, 2024 Eyevance Pharmaceuticals announced a worldwide licensing agreement with OcuNexus Therapeutics for Nexagon, a 30-base antisense oligomer being developed …See details»
OcuNexus Therapeutics, Inc. - Drug pipelines, Patents, Clinical …
Apr 1, 2024 Explore OcuNexus Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 8 clinical trials, 1 news, Disease Domain:Endocrinology and …See details»
Eyevance Pharmaceuticals Acquires Worldwide Rights to …
Oct 2, 2018 OcuNexus therapeutics is a clinical stage biopharmaceutical company developing highly differentiated drug candidates based upon novel connexin43 …See details»
Eyevance Pharmaceuticals Acquires Worldwide Rights to …
Oct 3, 2018 OcuNexus therapeutics is a clinical stage biopharmaceutical company developing highly differentiated drug candidates based upon novel connexin43 …See details»
InflammX Therapeutics, Inc.
InflammX Therapeutics is a clinical-stage company with highly differentiated, first-in-class products based upon a novel mechanism called “Connexin43 (Cx43) Hemichannel …See details»
HCB 1019 - AdisInsight - Springer
Mar 25, 2021 Contact Us. Institution access. Drug Profile. HCB 1019. Alternative Names: HCB-1019. Latest Information Update: 25 Mar 2021. Price : $50 * Buy Profile. Adis is an …See details»
Lufepirsen - OcuNexus Therapeutics - AdisInsight - Springer
Aug 8, 2023 Lufepirsen is connexin43 antisense oligonucleotide (30-mer) compound in a slow-release gel formulation [Nexagon®], being developed by OcuNexus Therapeutics.See details»
Ocunexus Therapeutics - Crunchbase
Ocunexus Therapeutics is a biopharmaceutical company that develops therapeutics for unmet clinical needs in ophthalmology.See details»
Peptagon - OcuNexus Therapeutics - AdisInsight
Peptagon, a peptidomimetic of peptide 5 and a hemi-channel blocker (gap junction inhibitor), is being developed by OcuNexus Therapeutics for the treatment of.See details»
Lykos Therapeutics Strengthens Commercial Organization with …
1 day ago Lykos Therapeutics ("Lykos"), a company dedicated to transforming mental healthcare, announced Allison Rosenthal has been appointed Chief Commercial Officer …See details»